AAAishah Alattas

Aishah Alattas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aishah Alattas has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring the Perceptions of mHealth Interventions for the Prevention of Common Mental Disorders in University Students in Singapore: Qualitative Study

    by Alicia Salamanca-Sanabria, Ahmad Ishqi Jabir, Xiaowen Lin, Aishah Alattas, A Baki Kocaballi, Jimmy Lee, Tobias Kowatsch, Lorainne Tudor Car

    Background: Mental health interventions delivered through mobile health (mHealth) technologies can increase the access to mental health services, especially among university students. The development of mHealth intervention is complex and needs to be context sensitive. There is currently limited evidence on the perceptions, needs, and barriers related to these interventions in the Southeast Asian context. Objective: This qualitative study aimed to explore the perception of university students and mental health supporters in Singapore about mental health services, campaigns, and mHealth interventions with a focus on conversational agent interventions for the prevention of common mental disorders such as anxiety and depression. Methods: We conducted 6 web-based focus group discussions with 30 university students and one-to-one web-based interviews with 11 mental health supporters consisting of faculty members tasked with student pastoral care, a mental health first aider, counselors, psychologists, a clinical psychologist, and a psychiatrist. The qualitative analysis followed a reflexive thematic analysis framework. Results: The following 6 main themes were identified: a healthy lifestyle as students, access to mental health services, the role of mental health promotion campaigns, preferred mHealth engagement features, factors that influence the adoption of mHealth interventions, and cultural relevance of mHealth interventions. The interpretation of our findings shows that students were reluctant to use mental health services because of the fear of stigma and a possible lack of confidentiality. Conclusions: Study participants viewed mHealth interventions for mental health as part of a blended intervention. They also felt that future mental health mHealth interventions should be more personalized and capable of managing adverse events such as suicidal ideation.


  • Open Access

    Exploring the Perceptions of mHealth Interventions for the Prevention of Common Mental Disorders in University Students in Singapore: Qualitative Study (Preprint)

    by Alicia Salamanca-Sanabria, Ahmad Ishqi Jabir, Xiaowen Lin, Aishah Alattas, A Baki Kocaballi, Jimmy Lee, Tobias Kowatsch, Lorainne Tudor Car

    BACKGROUND Mental health interventions delivered through mobile health (mHealth) technologies can increase the access to mental health services, especially among university students. The development of mHealth intervention is complex and needs to be context sensitive. There is currently limited evidence on the perceptions, needs, and barriers related to these interventions in the Southeast Asian context. OBJECTIVE This qualitative study aimed to explore the perception of university students and mental health supporters in Singapore about mental health services, campaigns, and mHealth interventions with a focus on conversational agent interventions for the prevention of common mental disorders such as anxiety and depression. METHODS We conducted 6 web-based focus group discussions with 30 university students and one-to-one web-based interviews with 11 mental health supporters consisting of faculty members tasked with student pastoral care, a mental health first aider, counselors, psychologists, a clinical psychologist, and a psychiatrist. The qualitative analysis followed a reflexive thematic analysis framework. RESULTS The following 6 main themes were identified: a healthy lifestyle as students, access to mental health services, the role of mental health promotion campaigns, preferred mHealth engagement features, factors that influence the adoption of mHealth interventions, and cultural relevance of mHealth interventions. The interpretation of our findings shows that students were reluctant to use mental health services because of the fear of stigma and a possible lack of confidentiality. CONCLUSIONS Study participants viewed mHealth interventions for mental health as part of a blended intervention. They also felt that future mental health mHealth interventions should be more personalized and capable of managing adverse events such as suicidal ideation.

  • Open Access

    Top-Funded Companies Offering Digital Health Interventions for the Prevention and Treatment of Depression: A Systematic Market Analysis (Preprint)

    by Alicia Salamanca-Sanabria, Oscar Castro, Aishah Alattas, Gisbert W Teepe, Konstantin Leidenberger, Elgar Fleisch, Loraine Tudor Car, Falk Mueller-Riemenschneider, Tobias Kowatsch

    BACKGROUND Digital innovations in the mental health care field provide an opportunity to mitigate the global burden of mental disorders such as depression by facilitating timely, accessible, scalable, and affordable interventions. However, there is little evidence on how much these interventions rely on novel automated approaches, such as conversational agents (CAS), just-in-time adaptive interventions (JITAIs), or low-burden sensing technologies. OBJECTIVE Our objectives were: (i) to identify the top-funded companies offering digital health interventions for the prevention and treatment of depression (DHID), (ii) to review DHIDs’ scientific evidence, (iii) to identify which psychotherapy approaches are being used, and (iv) to examine the degree to which these DHIDs include novel automated approaches such as CAs, JITAIs, and low-burden sensing technologies. METHODS A systematic search was conducted using two venture capital databases (Crunchbase and Pitchbook) to identify the top 30 funded companies offering DHIDs. In addition, studies related to the DHIDs were identified via scientific databases (PubMed, Cochrane Library, and APA Psych-info) and hand-searching (companies’ websites). RESULTS The top-30 funded companies offering DHIDs received total funding of 2’592 billion USD up to February 2022. A total of 83 studies were identified by fewer than half of the companies (n=14; 46.6%), of which only 8 (n= 26.6%) employed a randomized controlled trial design. Cognitive-behavioural therapy is the most commonly used psychotherapy approach (n=25, 83.3%), whereas behavioural activation and/or interpersonal therapy (the most effective interventions for depression) were used by only 8 companies (26.6%). Regarding novel technologies, only a few companies incorporated the use of CAs (n=8, 26.6%), or low-burden sensing technologies such as biofeedback-based breathing training with heart rate measurements (n=3, 10%), and only one used a biomarker for depression based on voice features (3.33%). CONCLUSIONS Findings suggest that the amount of funding is not related to the evidence. There is a strong variation in the quantity of evidence provided and an overall need for more rigorous effectiveness trials. Few DHIDs use automated approaches such as CAs and JITAIs, limiting their scalability and delivery of actionable support at the most opportune moments. CLINICALTRIAL N/A


  • Open Access

    Digital Behavior Change Interventions for the Prevention and Management of Type 2 Diabetes: Systematic Market Analysis

    by Roman Keller, Sven Hartmann, Gisbert Wilhelm Teepe, Kim-Morgaine Lohse, Aishah Alattas, Lorainne Tudor Car, Falk Müller-Riemenschneider, Florian von Wangenheim, Jacqueline Louise Mair, Tobias Kowatsch

    Background: Advancements in technology offer new opportunities for the prevention and management of type 2 diabetes. Venture capital companies have been investing in digital diabetes companies that offer digital behavior change interventions (DBCIs). However, little is known about the scientific evidence underpinning such interventions or the degree to which these interventions leverage novel technology-driven automated developments such as conversational agents (CAs) or just-in-time adaptive intervention (JITAI) approaches. Objective: Our objectives were to identify the top-funded companies offering DBCIs for type 2 diabetes management and prevention, review the level of scientific evidence underpinning the DBCIs, identify which DBCIs are recognized as evidence-based programs by quality assurance authorities, and examine the degree to which these DBCIs include novel automated approaches such as CAs and JITAI mechanisms. Methods: A systematic search was conducted using 2 venture capital databases (Crunchbase Pro and Pitchbook) to identify the top-funded companies offering interventions for type 2 diabetes prevention and management. Scientific publications relating to the identified DBCIs were identified via PubMed, Google Scholar, and the DBCIs’ websites, and data regarding intervention effectiveness were extracted. The Diabetes Prevention Recognition Program (DPRP) of the Center for Disease Control and Prevention in the United States was used to identify the recognition status. The DBCIs’ publications, websites, and mobile apps were reviewed with regard to the intervention characteristics. Results: The 16 top-funded companies offering DBCIs for type 2 diabetes received a total funding of US $2.4 billion as of June 15, 2021. Only 4 out of the 50 identified publications associated with these DBCIs were fully powered randomized controlled trials (RCTs). Further, 1 of those 4 RCTs showed a significant difference in glycated hemoglobin A1c (HbA1c) outcomes between the intervention and control groups. However, all the studies reported HbA1c improvements ranging from 0.2% to 1.9% over the course of 12 months. In addition, 6 interventions were fully recognized by the DPRP to deliver evidence-based programs, and 2 interventions had a pending recognition status. Health professionals were included in the majority of DBCIs (13/16, 81%,), whereas only 10% (1/10) of accessible apps involved a CA as part of the intervention delivery. Self-reports represented most of the data sources (74/119, 62%) that could be used to tailor JITAIs. Conclusions: Our findings suggest that the level of funding received by companies offering DBCIs for type 2 diabetes prevention and management does not coincide with the level of evidence on the intervention effectiveness. There is considerable variation in the level of evidence underpinning the different DBCIs and an overall need for more rigorous effectiveness trials and transparent reporting by quality assurance authorities. Currently, very few DBCIs use automated approaches such as CAs and JITAIs, limiting the scalability and reach of these solutions.


  • Open Access

    Digital Behavior Change Interventions for the Prevention and Management of Type 2 Diabetes: Systematic Market Analysis (Preprint)

    by Roman Keller, Sven Hartmann, Gisbert Wilhelm Teepe, Kim-Morgaine Lohse, Aishah Alattas, Lorainne Tudor Car, Falk Müller-Riemenschneider, Florian von Wangenheim, Jacqueline Louise Mair, Tobias Kowatsch

    BACKGROUND Advancements in technology offer new opportunities for the prevention and management of type 2 diabetes. Venture capital companies have been investing in digital diabetes companies that offer digital behavior change interventions (DBCIs). However, little is known about the scientific evidence underpinning such interventions or the degree to which these interventions leverage novel technology-driven automated developments such as conversational agents (CAs) or just-in-time adaptive intervention (JITAI) approaches. OBJECTIVE Our objectives were to identify the top-funded companies offering DBCIs for type 2 diabetes management and prevention, review the level of scientific evidence underpinning the DBCIs, identify which DBCIs are recognized as evidence-based programs by quality assurance authorities, and examine the degree to which these DBCIs include novel automated approaches such as CAs and JITAI mechanisms. METHODS A systematic search was conducted using 2 venture capital databases (Crunchbase Pro and Pitchbook) to identify the top-funded companies offering interventions for type 2 diabetes prevention and management. Scientific publications relating to the identified DBCIs were identified via PubMed, Google Scholar, and the DBCIs’ websites, and data regarding intervention effectiveness were extracted. The Diabetes Prevention Recognition Program (DPRP) of the Center for Disease Control and Prevention in the United States was used to identify the recognition status. The DBCIs’ publications, websites, and mobile apps were reviewed with regard to the intervention characteristics. RESULTS The 16 top-funded companies offering DBCIs for type 2 diabetes received a total funding of US $2.4 billion as of June 15, 2021. Only 4 out of the 50 identified publications associated with these DBCIs were fully powered randomized controlled trials (RCTs). Further, 1 of those 4 RCTs showed a significant difference in glycated hemoglobin A1c (HbA1c) outcomes between the intervention and control groups. However, all the studies reported HbA1c improvements ranging from 0.2% to 1.9% over the course of 12 months. In addition, 6 interventions were fully recognized by the DPRP to deliver evidence-based programs, and 2 interventions had a pending recognition status. Health professionals were included in the majority of DBCIs (13/16, 81%,), whereas only 10% (1/10) of accessible apps involved a CA as part of the intervention delivery. Self-reports represented most of the data sources (74/119, 62%) that could be used to tailor JITAIs. CONCLUSIONS Our findings suggest that the level of funding received by companies offering DBCIs for type 2 diabetes prevention and management does not coincide with the level of evidence on the intervention effectiveness. There is considerable variation in the level of evidence underpinning the different DBCIs and an overall need for more rigorous effectiveness trials and transparent reporting by quality assurance authorities. Currently, very few DBCIs use automated approaches such as CAs and JITAIs, limiting the scalability and reach of these solutions.